Study Summary
This trial compared two different treatment regimens for people with previously untreated CLL or SLL.
- Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 11 Secondary · Reporting Duration: Date of randomization until PD (Assessed Up to 6.6 Years)
Trial Safety
Safety Progress
Side Effects for
Trial Design
2 Treatment Groups
Arm A: Acalabrutinib plus Venetoclax (AV)
1 of 2
Arm B: Venetoclax plus Obinutuzumab (VO)
1 of 2
Experimental Treatment
600 Total Participants · 2 Treatment Groups
Primary Treatment: Acalabrutinib · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 130 · All Participants · 11 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Ryan, Christine E, Matthew S Davids, Richard Hermann, Mina Shahkarami, Juliana Biondo, Sarang Abhyankar, Hasan Alhasani, Jeff P Sharman, Anthony R Mato, and Lindsey E Roeker. 2022. “MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax Versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma”. Future Oncology. Future Medicine Ltd. doi:10.2217/fon-2022-0456.
- Ryan CE, Davids MS, Hermann R, Shahkarami M, Biondo J, Abhyankar S, Alhasani H, Sharman JP, Mato AR, Roeker LE. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 2022 Sep 14:0. doi: 10.2217/fon-2022-0456. Online ahead of print.
- Ryan CE, Davids MS, Hermann R, Shahkarami M, Biondo J, Abhyankar S, Alhasani H, Sharman JP, Mato AR, Roeker LE. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 2022 Oct;18(33):3689-3699. doi: 10.2217/fon-2022-0456. Epub 2022 Sep 14.
- Ryan CE, Davids MS, Hermann R, Shahkarami M, Biondo J, Abhyankar S, Alhasani H, Sharman JP, Mato AR, Roeker LE. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 2022 Oct;18(33):3689-3699. doi: 10.2217/fon-2022-0456. Epub 2022 Sep 14. Erratum In: Future Oncol. 2023 Jan 19;:
- 2022. "A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05057494.
Frequently Asked Questions
What autoimmune diseases does Acalabrutinib typically help to manage?
"Acalabrutinib is frequently used to treat small lymphocytic lymphoma. However, it can also ameliorate symptoms for patients suffering from lymphoid leukemia, ≥ 1 prior therapy for mantle cell lymphoma, and refractory follicular lymphoma." - Anonymous Online Contributor
How can I become a subject in this experiment?
"This study is seeking 600 participants with lymphoma who are aged 18 or older. Candidates should meet the following criteria: Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations)., Participant must be ≥ 18 years at the time of screening., Documented TN CLL/SLL requiring treatment according to iwCLL guidelines 2018 (Hallek et al 2018)., Absolute neutrophil count ≥ 1.0 × 10 9 /L., Platelet counts ≥ 30 × 10 9 /L; in" - Anonymous Online Contributor
What other research has been conducted with Acalabrutinib?
"Acalabrutinib was first studied in 2012 at CHU de Dijon. As of now, there have been 123 completed trials with 350 more currently underway. The majority of these active studies are taking place in Jacksonville, Florida." - Anonymous Online Contributor
In how many different medical clinics is this medical study being run today?
"There are 17 locations currently enrolling patients for this study, with participating clinics located in Jacksonville, Longmont, Buffalo and 14 other cities. To minimize potential travel requirements, it is recommended that you select the clinic nearest to your location." - Anonymous Online Contributor
Could you list some of the potential Acalabrutinib side effects?
"Acalabrutinib's safety is well-documented, as this drug has reached Phase 3 in clinical trials." - Anonymous Online Contributor
Is this research study open to elderly participants?
"This particular study is looking for clinical trial participants that are aged 18-130. Out of the 3,544 total trials, 655 focus on children and 2889 involve senior citizens." - Anonymous Online Contributor
How many individuals are allowed to participate in this experiment?
"That is correct. The clinical trial in question, which was posted on September 12th, 2022 and edited October 3rd, 2022 according to information available on clinicaltrials.gov, is currently recruiting 600 patients from 17 different locations." - Anonymous Online Contributor
Are researchers still looking for participants in this trial?
"Yes, this is an active trial according to the information provided on clinicaltrials.gov. The listing for the study says that it was posted on 9/12/2022 and last updated on 10/3/2022. They are looking for 600 patients total from 17 different locations." - Anonymous Online Contributor